Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial

Journal:

Nature Medicine

Published:

2026-05-13

DOI:

10.1038/s41591-026-04386-7

Affiliations:

8

Authors:

14

Go to article

Institutions	Authors	Share
Lilly, United States of America (USA)	8.000000	0.57
Weill Cornell Medicine, United States of America (USA)	1.000000	0.07
The University of Texas Health Science Center at Houston (UTHealth), United States of America (USA)	1.000000	0.07
Johns Hopkins University (JHU), United States of America (USA)	1.000000	0.07
University of Southern California (USC), United States of America (USA)	1.000000	0.07
Hospital Nove de Julho, Brazil	1.000000	0.07
University College Dublin (UCD), Ireland	0.500000	0.04
University of Ulster (UU), United Kingdom (UK)	0.500000	0.04

Interested in Pharmacology and Pharmaceutical Sciences?